Abrisqueta, P., González-Barca, E., Ferrá, C., Ríos-Herranz, E., Fernández de la Mata, M., Delgado, J., . . . Bosch, F. (2024). Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).
Citação norma ChicagoAbrisqueta, Pau, et al. Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial From the Spanish Group of CLL (GELLC). 2024.
Citação norma MLAAbrisqueta, Pau, et al. Ibrutinib Followed By Ofatumumab Consolidation in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL): GELLC-7 Trial From the Spanish Group of CLL (GELLC). 2024.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.